Back to news

IRulya Therapeutics to Participate in the 9th Annual Evercore Healthcare Conference

Globe Newswire•19/11/2026•08:00 ET
0

Key Highlights

  • ➤IRulya (IRLA) management to join Evercore Healthcare Conference fireside chat November 30
  • ➤LAM-001 Phase 2b PH-ILD clinical study is ongoing
  • ➤LAM-001 Phase 2 BOS clinical study is ongoing
  • ➤LAM-001 Phase 2 SAPH clinical study anticipated to begin fourth quarter 2026

NEW HAVEN, Conn., Nov. 19, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that senior management will participate in a fireside chat at the 9(th) Annual Evercore Healthcare Conference on November 30, 2026 at 12:55 PM EST.

A webcast of the event will be accessible by visiting the “Events” section on the “Investors” page of IRulya’s website at www.irulya.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in